Speaker: Rates of adverse events comparable for ocriplasmin in clinical trials, postmarket data

MIAMI — Despite "vastly different methodology" in data capture between the clinical trial program for ocriplasmin as a treatment for symptomatic vitreomacular adhesion and the postmarketing analyses, which may be "woefully underreported," comparable frequencies of adverse events are seen between the two, Baruch D. Kuppermann, MD, said here. "We're trying to get a handle on adverse events. It's a new product. There are adverse events that are occurring. It is important for us to understand them so we can set both physician and patient expectations," Kuppermann said at the Angiogenesis, (Read more...)

Full Story →